Hypothesis
The NIK‑HK2 metabolic checkpoint sets a temporal boundary after which T‑cell exhaustion becomes epigenetically locked and unresponsive to combined NLRP3 inflammasome inhibition and senolytic clearance of inflammatory senescent cells.
Mechanistic rationale
Chronic low‑grade inflammation activates the canonical NLRP3 pathway, driving IL‑1β release and NF‑κB signaling. Simultaneously, non‑canonical NF‑κB via RelB induces TOX, a master transcription factor of exhaustion. Recent work shows that NIK preserves T‑cell metabolic fitness by stabilizing hexokinase 2 (HK2) and limiting ROS, independent of its role in NF‑κB activation [[https://pmc.ncbi.nlm.nih.gov/articles/PMC7855506/]]. We propose that high NIK‑HK2 activity maintains a NAD⁺‑dependent sirtuin activity that keeps the TOX promoter in a hypomethylated, plastic state. When metabolic stress reduces NIK or HK2, ROS rises, SIRT1 activity drops, and DNMT3A is recruited to the TOX locus, leading to CpG methylation that locks TOX expression. This epigenetic conversion creates a point of no return: even if NLRP3 is blocked (e.g., with MCC950 analogues) and senescent cells are cleared (with dasatinib + quercetin), TOX remains high and T cells stay exhausted.
Testable predictions
- In human peripheral blood or tumor‑infiltrating lymphocytes, a high NIK/HK2 ratio will correlate with low TOX promoter methylation and responsiveness to ex‑vivo treatment with MCC950 plus senolytics (increased IFN‑γ, reduced PD‑1).
- Conversely, samples with low NIK/HK2 will show high TOX methylation and fail to regain function de





























